PRESS RELEASE: MagForce AG Receives Further Patent Related to NanoTherm(R) Therapy

MagForce AG / MagForce AG Receives Further Patent Related to NanoTherm(R) Therapy . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

-- European patent granted for nanoparticle-drug conjugates

-- MagForce further expands patent portfolio

Berlin, Germany, May 7, 2013 - MagForce AG (Frankfurt, XETRA: MF6), a leading medical technology company in the field of nanomedicine in oncology, announced today that the Company has been granted a further European patent for its NanoTherm(R) therapy, for which the opposition period has now expired. Patent EP 1871423 B1 relates to a new generation of NanoTherm(R) particles in the form of nanoparticle-drug conjugates, which are suitable for drug delivery systems. Nanoparticle-drug conjugates inside a tumor can be heated selectively by an alternating magnetic field leading to a temperature-dependent release of the drug inside the tumor tissue producing a high local drug concentration. Additionally the known synergistic effects of chemotherapy in combination with hyperthermia can be utilized.

"The locally limited and externally controllable drug release by means of the now patent-protected conjugates is expected to clearly reduce the mostly considerable side-effects of conventional chemotherapeutic agents. Combining thermotherapy with nanoparticle-bound chemotherapy could also substantially increase the effectiveness of the chemotherapeutic agent in tumor treatment and reduce the number of nanoparticles required to destroy the cancer cells," commented Prof. Dr. Hoda Tawfik, COO and co-CEO of MagForce. "We are very pleased to have been granted a further patent for our NanoTherm(R) therapy. By expanding our patent portfolio we will improve protection of our intellectual property and strengthen our competitive position."

About NanoTherm(R) Therapy

The NanoTherm(R) Therapy is a new approach for the local treatment of solid tumors. The principle of the method is the direct introduction of superparamagnetic nanoparticles into a tumor and their subsequent heating in an alternating magnetic field. The nanoparticles are extremely small (approximately 15 nanometers in diameter) and contain an iron oxide core with an aminosilane coating. The particles are activated by a magnetic field that changes its polarity 100,000 times per second, and heat is produced. Depending on the duration of treatment and the achieved intratumoral temperatures, the tumor cells are either directly destroyed (thermal ablation) or sensitized for concomitant chemotherapy or radiotherapy (hyperthermia). With this new therapeutic approach, it is possible to combat the tumor from the inside out, thereby sparing surrounding healthy tissue. The nanoparticles remain in place at the treatment area, allowing for repeat treatments and the integration of multimodal therapy concepts. NanoTherm(R) Therapy has regulatory approval in 27 European countries.

About MagForce AG

MagForce AG is a leading medical technology company in the field of nanomedicine in oncology. The Company's proprietary, NanoTherm(R) therapy, enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. NanoTherm(R) , NanoPlan(R) , and NanoActivator(TM) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm(R) , NanoPlan(R) , and NanoActivator(TM) are trademarks of MagForce AG in selected countries. For more information, please visit www.magforce.com.

Disclaimer

This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.

MagForce_Press Release_May 07, 2013: http://hugin.info/143761/R/1699666/560772.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the

information contained therein.

Source: MagForce AG via Thomson Reuters ONE

HUG#1699666

--- End of Message ---

MagForce AG

Max-Dohrn-Str. 8 Berlin Germany

WKN: A0HGQF;ISIN: DE000A0HGQF5;

Listed: Open Market (Freiverkehr) in Frankfurter Wertpapierbörse;

http://www.magforce.de/english/home1.html (END) Dow Jones Newswires

   May 07, 2013 03:01 ET (07:01 GMT)- - 03 01 AM EDT 05-07-13